Why Absci Corporation’s (ABSI) Stock Is Up 7.65%
As of Friday, August 21, Absci Corporation’s ABSI share price has surged by 7.65%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Commentary & Analysis
Why Absci Corporation’s (ABSI) Stock Is Up 8.93%
As of Wednesday, August 19, Absci Corporation’s ABSI share price has surged by 8.93%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Absci Corporation’s (ABSI) Stock Is Down 6.06%
As of Tuesday, August 18, Absci Corporation’s ABSI share price has dipped by 6.06%, which has investors questioning if this is right time to buy.Michael Rose
Why Absci Corporation’s (ABSI) Stock Is Down 5.07%
As of Friday, August 14, Absci Corporation’s ABSI share price has dipped by 5.07%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
What You Need to Know About Absci Corporation's Q3 Earnings
Absci Corporation's fiscal Q3 earnings report was released on Tuesday, August 11. Let's dive in to see if (ABSI) missed or beat analyst's expectations.Jenna Brashear
Financial Summary
| Share Statistics | ABSI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,592.6 | $286.3 | 51% |
|
| Shares Out (Mil) | 157.5 | 54.2 | 72% |
|
| Institutional Ownership | 94.6% | 92.8% | 65% |
|
| Float (Mil) | 163.8 | 39.7 | 71% |
|
| Beta | 2.42 | 0.94 | 96% |
|
| Avg Daily Volume (000s) | 2,892 | 534 | 87% |
|
| Price Change (52-week) |
254.2% | 58.7% | 98% |
|
| Growth | ABSI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (10.2%) | 13.6% | 5% |
|
| Net Income (5yr) | (51.6%) | (10.1%) | 7% |
|
| EPS (5yr) | 23.4% | 16.0% | 73 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.7%) | (15.6%) | 47% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.202) | ($0.806) | ($0.675) | |
| Month Ago EPS | ($0.199) | ($0.778) | ($0.623) | |
| # Rev Up | 1 | 2 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.205) | ($0.765) | ($0.624) | |
| Year/Year Chg | (4.3%) | (4.3%) | (37.3%) | |
| Financials | ABSI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $37 | 3% |
|
| Net Income (TTM) (Mil) | ($121) | ($43) | 10% |
|
| EPS (TTM) | ($0.800) | ($1.400) | 23% |
|
| Operating Cash Flow (TTM) (Mil) | ($108) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $54 | $2 | 71% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 19% |
|
| Enterprise Value (Q1) (Mil) | $1,433 | $160 | 45% |
|
| Valuation | ABSI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.49 | 2.77 | 83% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ABSI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (50.6%) | (47.3%) | 11% |
|
| ROE | (57.7%) | (55.0%) | 14% |
|
| Liabilities to Assets | 8.5% | 29.6% | 5% |
|
| F-Score | 3 | 2 | 18% |
|
Absci Corporation did not pass any screens on 8/20/2026.
